One diabetes drug class linked to lower dementia risk than insulin
Dementia rates were 4.86 per 1,000 person-years among users of the drug class, versus 7.56 among long-acting insulin users.
10,783 participants
Limit: Insurance claims can miss or misclassify dementia diagnoses
Edited by Boris Djordjevic · AgingResearch.News
In Taiwan, a retrospective cohort study compared 10,783 matched pairs of adults over 50 with type 2 diabetes who started diabetes medicines between 2011 and 2021. One group started glucagon-like peptide-1 receptor agonists, a class of diabetes drugs; the other started long-acting insulin. Researchers matched the groups on age, sex, existing conditions and other medication use.
Insurance records identified 375 new dementia diagnoses. Use of the drug class was associated with lower dementia risk after researchers accounted for measured differences between the groups. The association also appeared for dementia classified as unspecified. The study found no clear association for Alzheimer’s disease or vascular dementia, which involves problems with blood supply to the brain.
Why it matters
Dementia is an age-related condition. This comparison bears on whether diabetes medication choices might also matter for dementia prevention.
Caveats
This observational study could not establish causation, and researchers identified dementia through insurance claims. The findings concern adults over 50 with type 2 diabetes and no previous dementia, not younger people or people without diabetes.
The paper
Fu Jen Catholic University; China Medical University
The Journal of Prevention of Alzheimer's Disease, Aug 8, 2026, Open access
